Pirtobrutinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 190 publications

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma
Published: June 21, 2026

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Journal: Expert opinion on drug discovery
Published: June 15, 2026

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Journal: Expert opinion on pharmacotherapy
Published: May 29, 2026

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk.

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk.

Journal: Cancers
Published: April 19, 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Journal: Pharmacological research
Published: March 31, 2026

Pirtobrutinib approved to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pirtobrutinib approved to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

Journal: The American journal of nursing
Published: March 26, 2026

Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies.

Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies.

Journal: Journal of biomolecular structure & dynamics
Published: March 23, 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 13, 2026

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review.

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review.

Journal: Cureus
Published: March 02, 2026

Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review.

Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review.

Journal: Expert review of clinical immunology
Published: February 19, 2026

Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.

Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.

Journal: Circulation
Published: February 09, 2026

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

Journal: HemaSphere
Published: February 06, 2026
Showing 1-12 of 190

Last Updated: 06/30/2026